Production (Stage)
Haemonetics Corporation
HAE
$66.06
-$0.10-0.15%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.95% | 8.14% | 9.84% | 9.47% | 12.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.95% | 8.14% | 9.84% | 9.47% | 12.01% |
| Cost of Revenue | -1.86% | 4.45% | 5.76% | 6.08% | 9.41% |
| Gross Profit | 8.83% | 11.26% | 13.41% | 12.45% | 14.30% |
| SG&A Expenses | -1.01% | 3.44% | 6.58% | 12.11% | 13.17% |
| Depreciation & Amortization | 50.67% | 60.21% | 36.83% | 16.64% | -1.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.88% | 6.14% | 7.19% | 8.62% | 10.30% |
| Operating Income | 20.54% | 18.71% | 24.89% | 14.04% | 22.26% |
| Income Before Tax | 39.64% | 2.28% | -0.26% | -12.25% | 7.40% |
| Income Tax Expenses | 29.40% | 0.52% | 13.08% | 3.77% | 31.94% |
| Earnings from Continuing Operations | 42.64% | 2.76% | -3.48% | -15.87% | 1.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.64% | 2.76% | -3.48% | -15.87% | 1.87% |
| EBIT | 20.54% | 18.71% | 24.89% | 14.04% | 22.26% |
| EBITDA | 21.24% | 20.67% | 22.97% | 13.04% | 16.29% |
| EPS Basic | 44.10% | 2.55% | -4.07% | -16.21% | 1.99% |
| Normalized Basic EPS | 17.72% | 15.94% | 25.13% | 18.58% | 25.52% |
| EPS Diluted | 44.92% | 3.25% | -3.22% | -15.85% | 2.69% |
| Normalized Diluted EPS | 18.36% | 16.49% | 25.55% | 18.78% | 25.42% |
| Average Basic Shares Outstanding | -0.74% | 0.21% | 0.58% | 0.38% | -0.15% |
| Average Diluted Shares Outstanding | -1.30% | -0.27% | 0.24% | 0.23% | -0.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |